Ubs Oconnor LLC Biocryst Pharmaceuticals Inc Transaction History

Ubs Oconnor LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $134,616 - $210,596	-27,529 Reduced 45.76%	32,630 $165,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $904,671 - $1.23 Million	-181,661 Reduced 75.12%	60,159 $360,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $62,785 - $74,107	9,357 Added 4.03%	241,820 $1.71 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $1.62 Million - $2.05 Million	232,463 New	232,463 $1.64 Billion
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $152,837 - $227,908	-19,249 Reduced 7.86%	225,764 $1.88 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $301,203 - $407,341	28,686 Added 13.26%	245,013 $0
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $215,799 - $296,200	-20,000 Reduced 8.46%	216,327 $2.73 Billion
Q2 2022 Aug 12, 2022	BUY	$7.89 - $17.88 $1.52 Million - $3.44 Million	192,527 Added 439.56%	236,327 $2.5 Million
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $506,328 - $865,488	43,800 New	43,800 $712,000

278

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.